ID: h-71cd255f48
Hypothesis
Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synuclein clearance at physiological SCFA concentrations
The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition, not on the low systemic concentrations realistically achievable with diet or probiotics.
EvidencePending (0%)📖 7 cit🗣 1 debates✓ 7 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition, not on the low systemic concentrations realistically achievable with diet or probiotics. This should be treated as a negative control or deprioritized mechanism rather than a leading therapeutic explanation for physiologic SCFA effects.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Transcription Factor Recruitment<br/>Histone Deacetylase Corepressor Complex"]
B["HDAC1/HDAC2 Rpd3L Engagement<br/>Nascent Transcript Association"]
C["Inflammatory Gene Repression<br/>NF-kB and STAT1 Target Suppression"]
D["Microglial Homeostasis<br/>Pro-inflammatory Resolution"]
E["HDAC1/HDAC2 Inhibitor Exposure<br/>Chromatin Opening and Reactivation"]
F["Epigenetic Plasticity Restoration<br/>Gene Program Rebalancing"]
A --> B
B --> C
C --> D
E --> F
F -.->|"counteracts"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8⚖️ Evidence
⚖️ Evidence Matrix7 supports1 contradicts
Supports
Butyrate rescued alpha-syn-induced transcriptional defects in dopaminergic cell models, but this literature reflects pharmacologic HDAC-inhibitor-like exposure rather than physiological in vivo levels.
Supports
Human circulating SCFAs are low, making direct neuronal nuclear exposure sufficient for canonical HDAC inhibition unlikely.
Supports
Kirenol alleviates cerebral ischemic injury by promoting synaptic plasticity via HDAC2-mediated BDNF expression.
Supports
Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease.
Supports
Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.
Supports
Inhibition of histone deacetylase promotes a neuroprotective mechanism in an experimental model of Parkinson's disease.
Supports
Electroacupuncture alleviates Parkinson's disease by targeting HDAC/SIRT-mediated deacetylation of 14-3-3.
Contradicts
Current evidence does not fully exclude indirect in vivo acetylation changes downstream of endocrine or inflammatory effects.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HDAC1
No curated PDB or AlphaFold mapping for HDAC1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HDAC1/HDAC2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HDAC1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.3%
Volatility
Low
0.0040
Events (7d)
2
Price History
▼4.6%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary cortical neurons are treated with physiologically relevant SCFA concentrations (butyrate 0.1–1 mM or propionate 0.05–0.5 mM for 48 hours), THEN neuronal HDAC activity will not decrease by m | HDAC activity assays (fluorometric) will show ≤15% inhibition at all physiological SCFA concentrations tested, while pharmacologic controls (5 mM butyrate) will | — no observation — | pending | 0.78 |
| IF mice with AAV-mediated alpha-synuclein overexpression are administered oral SCFA (butyrate 150 mg/kg/day or propionate 100 mg/kg/day) for 12 weeks to achieve physiological plasma concentrations (≤1 | Stereological quantification of pSer129-positive inclusions in striatum will show no significant difference (≤20% change) between physiologic SCFA treatment and | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 78%
IF primary cortical neurons are treated with physiologically relevant SCFA concentrations (butyrate 0.1–1 mM or propionate 0.05–0.5 mM for 48 hours), THEN neuronal HDAC activity will not decrease by more than 15% relative to vehicle control, because HDAC inhibition does not occur at these concentrat
Predicted outcome: HDAC activity assays (fluorometric) will show ≤15% inhibition at all physiological SCFA concentrations tested, while pharmacologic controls (5 mM buty
Falsification: If HDAC activity decreases by >30% at any physiological SCFA concentration (0.1–1 mM), the hypothesis is disproven and direct neuronal HDAC inhibition must be considered viable at these concentrations
pendingconf 72%
IF mice with AAV-mediated alpha-synuclein overexpression are administered oral SCFA (butyrate 150 mg/kg/day or propionate 100 mg/kg/day) for 12 weeks to achieve physiological plasma concentrations (≤1 mM), THEN striatal phosphorylated alpha-synuclein (pSer129) will not decrease by more than 20% rela
Predicted outcome: Stereological quantification of pSer129-positive inclusions in striatum will show no significant difference (≤20% change) between physiologic SCFA tre
Falsification: If striatal pSer129 alpha-synuclein burden decreases by >40% at physiological SCFA dosing, the hypothesis is disproven and therapeutic alpha-synuclein clearance via this mechanism at achievable concen
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.